button bars forest bayes pooled summary circles
 
DCR

lung cancer : non small cell (NSCLC) lung cancer : non small cell (NSCLC)

locally advanced NSCLC - (neo)adjuvant (NA) locally advanced NSCLC - (neo)adjuvant (NA)

versus placebo plus SoC
nivolumab plus SoC vs. placebo plus SoC 1 -

laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population

versus placebo
durvalumab alone vs. placebo 1 -

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC 1 -
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC) 1 -
durvalumab alone vs. Standard of Care (SoC) 1 -

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

versus pemetrexed plus platin
nivolumab plus SoC vs. pemetrexed plus platin 1 -

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 -
cemiplimab vs. Standard of Care (SoC) 1 -
durvalumab alone vs. Standard of Care (SoC) 1 -
nivolumab alone vs. Standard of Care (SoC) 2 -
pembrolizumab alone vs. Standard of Care (SoC) 4 -

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 -
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 -
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 -

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 -
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 -
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 -
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 -
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 -
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel
atezolizumab alone vs. docetaxel 2 -
avelumab alone vs. docetaxel 1 -
nivolumab alone vs. docetaxel 1 -
Tislelizumab vs. docetaxel 1 -

mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant

versus osimertinib
durvalumab plus osimertinib vs. osimertinib 1 -

mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
atezolizumab alone vs. docetaxel 1 -
avelumab alone vs. docetaxel 1 -
pembrolizumab (10mg/kg) vs. docetaxel 2 -
pembrolizumab (2mg/kg) vs. docetaxel 2 -
versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 -

non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population

versus docetaxel
nivolumab alone vs. docetaxel 1 -

squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population

versus docetaxel
nivolumab alone vs. docetaxel 1 -

NSCLC neoadjuvant setting NSCLC neoadjuvant setting

versus placebo plus SoC
nivolumab plus SoC vs. placebo plus SoC 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons